![](https://eresearch.com/wp-content/uploads/2020/08/2020-08-16-Xortx-FI.jpg)
XORTX Breaking Up the Code with Uric Acid
New 33-page Initiation Equity Research Report on XORTX, with a Speculative Buy rating and one-year price target of $2.30/share. The Company has two potential late stage drugs in development focused on kidney diseases that could initiate pivotal Phase 3 clinical trials in the next 12 months. [more]